Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

PURPOSE: Immunologic targeting of tumor-specific gene mutations may allow precise eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in g...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Sampson, John H., Heimberger, Amy B., Archer, Gary E., Aldape, Kenneth D., Friedman, Allan H., Friedman, Henry S., Gilbert, Mark R., Herndon, James E., McLendon, Roger E., Mitchell, Duane A., Reardon, David A., Sawaya, Raymond, Schmittling, Robert J., Shi, Weiming, Vredenburgh, James J., Bigner, Darell D.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2010
Sujets:
Original Reports
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3020702/
https://ncbi.nlm.nih.gov/pubmed/20921459
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.28.6963
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires